StreetInsider.com News Articles

Form 25-NSE SHINECO, INC. Filed by: Nasdaq Stock Market LLC

Thu, 20 Nov 2025 15:47:00 -0500

si-local-file:///var/storage/secattach/20251120/25644218.html

Form 25-NSE SHINECO, INC. Filed by: Nasdaq Stock Market LLC

Thu, 20 Nov 2025 15:47:00 -0500

si-local-file:///var/storage/secattach/20251120/25644218.html

Form 8-K SHINECO, INC. For: Oct 01

Wed, 08 Oct 2025 15:31:00 -0500

si-local-file:///var/storage/secattach/20251008/25435374.html

Form NT 10-K SHINECO, INC. For: Jun 30

Mon, 29 Sep 2025 06:15:00 -0500

si-local-file:///var/storage/secattach/20250929/25387430.html

Form NT 10-K SHINECO, INC. For: Jun 30

Mon, 29 Sep 2025 06:15:00 -0500

si-local-file:///var/storage/secattach/20250929/25387430.html

Shineco subsidiary signs $8.7M tech services contract

Fri, 12 Sep 2025 09:30:40 -0500

Shineco Inc. (NASDAQ: SISI) announced that its subsidiary Xi'an Dong'ao Health Management Co., Ltd. signed a technology services contract valued at $8.7 million with Xinke Future Biotechnology (Bazhou) Co., Ltd. for research and development of microalgae-derived extracellular vesicles technology.

The contract runs from August 25, 2025, to December 31, 2026. The company received an initial payment of $560,000, with subsequent payments tied to research and development milestones. The project aims to build a research and development system from basic research to product development, including functional validation and large-scale production processes.

Separately, a delegation from Singapore biotechnology company BICC visited Dong'ao Health from

Shineco (SISI) Ignites Growth: $8.7M Tech Deal & Major Singapore Alliance Unleash Dual Engines

Fri, 12 Sep 2025 09:30:00 -0500

BEIJING, Sept. 12, 2025 /PRNewswire/ -- Shineco Inc. (NASDAQ: SISI) ("Shineco" or the "Company"), a developer and commercializer of induced pluripotent stem cell (iPSC) technology platforms, today announced two major strategic advances. Its subsidiary, Xi'an Dong'ao Health Management Co., Ltd. ("Dong'ao Health"), has signed a technology services contract valued at US$8.7 million with Xinke Future Biotechnology (Bazhou) Co., Ltd. for the research and development of "microalgae-derived extracellular vesicles" technology. Separately, a delegation from Singapore's leading biotechnology company, BICC, completed a productive site visit to Dong'ao

Shineco (SISI) Ignites Growth: $8.7M Tech Deal & Major Singapore Alliance Unleash Dual Engines

Fri, 12 Sep 2025 09:30:00 -0500

Shineco (SISI) Ignites Growth: $8.7M Tech Deal & Major Singapore Alliance Unleash Dual Engines

Fri, 12 Sep 2025 09:30:00 -0500

Shineco (SISI) Ignites Growth: $8.7M Tech Deal & Major Singapore Alliance Unleash Dual Engines

Fri, 12 Sep 2025 09:30:00 -0500

Shineco subsidiary achieves mass production of high-purity phospholipids

Wed, 10 Sep 2025 09:30:47 -0500

Shineco Inc. (NASDAQ: SISI) announced that its subsidiary Fuzhou Meidashan Biotechnology Co., Ltd. has achieved large-scale production of high-purity soybean phospholipids using proprietary APCC-UF pure physical extraction technology.

The technology uses 70-80% pure water as solvent and fresh soybean colloid as raw material, eliminating chemical solvents through large-column chromatography combined with ultrafiltration membrane technology. Test reports show the lyophilized product contains 97.8% total phospholipid content and 50.2% phosphatidylcholine content, with no detectable solvent residues or heavy metals.

The company has completed validation on a thousand-ton production line with plans to expand to ten-thousand-ton capacity. Shineco states the single-batch yield is higher while

Shineco Achieves Mass Production of High-Purity Physical Phospholipids, Breaking Foreign Monopoly and Unlocking Innovation Across Industries

Wed, 10 Sep 2025 09:30:00 -0500

BEIJING, Sept. 10, 2025 /PRNewswire/ -- Shineco Inc. (NASDAQ: SISI) ("Shineco" or the "Company"), a leading developer of induced pluripotent stem cell (iPSC) technology platforms, today announced that its subsidiary, Fuzhou Meidashan Biotechnology Co., Ltd., has successfully achieved large-scale production of high-purity, highly active free-form soybean phospholipids. This breakthrough was made possible through its proprietary APCC-UF pure physical extraction technology, overcoming a persistent global technical challenge in the field. Testing by multiple authoritative institutions confirms that the product's key metrics meet internationally leading standards, providing robust technical support for the global upgrade of

Shineco Achieves Mass Production of High-Purity Physical Phospholipids, Breaking Foreign Monopoly and Unlocking Innovation Across Industries

Wed, 10 Sep 2025 09:30:00 -0500

Shineco Achieves Mass Production of High-Purity Physical Phospholipids, Breaking Foreign Monopoly and Unlocking Innovation Across Industries

Wed, 10 Sep 2025 09:30:00 -0500

Shineco Achieves Mass Production of High-Purity Physical Phospholipids, Breaking Foreign Monopoly and Unlocking Innovation Across Industries

Wed, 10 Sep 2025 09:30:00 -0500

Shineco (NASDAQ: SISI) & BICC: From "Tech On-Chain" to "Global Redeemability"--RWA Ecosystem Takes Off for Long-Term Growth

Wed, 27 Aug 2025 06:30:00 -0500

BEIJING, Aug. 27, 2025 /PRNewswire/ -- Shineco Inc. ("Shineco" or the "Company"; NASDAQ: SISI), a manufacturer of induced pluripotent stem cell (iPSC) technology platforms, has entered into a strategic cooperation agreement with Singapore-based BICC Pte Ltd to jointly promote the implementation and redemption of "on-chain cell assets" across multiple institutions and scenarios. This collaboration marks a new phase of "cross-enterprise redeemability" for cell assets on the blockchain, advancing the RWA ecosystem from "technical on-chain integration" to "real-world application.

This partnership builds on Shineco's

Shineco (NASDAQ: SISI) & BICC: From "Tech On-Chain" to "Global Redeemability"--RWA Ecosystem Takes Off for Long-Term Growth

Wed, 27 Aug 2025 06:30:00 -0500

This partnership builds on Shineco's

Shineco (NASDAQ: SISI) & BICC: From "Tech On-Chain" to "Global Redeemability"--RWA Ecosystem Takes Off for Long-Term Growth

Wed, 27 Aug 2025 06:30:00 -0500

This partnership builds on Shineco's

Shineco (NASDAQ: SISI) & BICC: From "Tech On-Chain" to "Global Redeemability"--RWA Ecosystem Takes Off for Long-Term Growth

Wed, 27 Aug 2025 06:30:00 -0500

This partnership builds on Shineco's

Shineco partners with Plus Me to tokenize cellular assets on blockchain

Wed, 20 Aug 2025 06:30:55 -0500

Shineco Inc. (NASDAQ: SISI) announced a partnership with blockchain infrastructure provider Plus Me Limited to tokenize biological cellular assets on the Ethereum blockchain. The collaboration will create digital tokens representing mesenchymal stem cells that can be redeemed at Shineco-affiliated cell therapy centers.

Under the agreement, Plus Me will deploy digital custody of Shineco's stem cells on the Ethereum mainnet using smart contracts. The system will issue non-fungible digital identifiers for each cellular asset and create ERC-1400/ERC-20 compliant security tokens called "Cell Infusion Redemption Tokens."

Shineco acquired a 51% controlling stake in Xi'an Dong'ao Health Management Co., Ltd. on August 18, 2025. The

Shineco Unveils World's First On-Chain Cell Asset Tokenization Platform; Strategic Acquisition Expands Global Blockchain-Biotech Network

Wed, 20 Aug 2025 06:30:00 -0500

BEIJING, Aug. 20, 2025 /PRNewswire/ -- Shineco Inc. ("Shineco" or the "Company"; NASDAQ: SISI), a leading innovator in induced pluripotent stem cell (iPSC) technology, today announced the execution of a "Cellular Asset On-Chaining and Marketing Ecosystem Cooperation Agreement" with blockchain infrastructure provider Plus Me Limited. This partnership enables blockchain-based tokenization of biological cellular assets, facilitating seamless global transfers and auditable standardized custody, creating a novel 'Asset On-Chaining + Application Scenarios' model in cell therapy. The collaboration will redefine the global biological cell industry's commercial architecture.

Under the agreement, Plus

Shineco Unveils World's First On-Chain Cell Asset Tokenization Platform; Strategic Acquisition Expands Global Blockchain-Biotech Network

Wed, 20 Aug 2025 06:30:00 -0500

Under the agreement, Plus

Shineco Unveils World's First On-Chain Cell Asset Tokenization Platform; Strategic Acquisition Expands Global Blockchain-Biotech Network

Wed, 20 Aug 2025 06:30:00 -0500

Under the agreement, Plus

Shineco Unveils World's First On-Chain Cell Asset Tokenization Platform; Strategic Acquisition Expands Global Blockchain-Biotech Network

Wed, 20 Aug 2025 06:30:00 -0500

Under the agreement, Plus

Shineco creates digital division to combine cell assets with blockchain

Wed, 13 Aug 2025 06:30:59 -0500

Shineco Inc. (NASDAQ: SISI) announced the establishment of a Biological Cell Digital Business Division and appointed Lin Hongguang as general manager to integrate the company's biological cell assets with blockchain technology.

The Beijing-based induced pluripotent stem cell technology platform manufacturer stated the division aims to build a blockchain-based ecosystem for managing biological cell assets. The division's objectives include promoting standardized management of biological cell assets, establishing an induced pluripotent stem cells cell bank, and creating compliance frameworks for asset traceability and security confirmation.

The division plans to develop blockchain tools including equity transfer mechanisms to address circulation inefficiencies in cell assets. The